Selection of Optimal Therapy at Correction of the Anemic Syndrome in Patients With Chronic Heart Failure

Purpose: to study efficacy of various schemes of therapy of patients with chronic heart failure (CHF) and anemia. Materials and methods. We included in this study 208 patients with CHF of ishemic etiology (mean age 60.6±1.4 years, 174 with and 34 without anemia). According to therapeutic regimen of the use of methoxy polyethylene glycol-epoetin beta (MEB, 0.60 mсg/kg) and intravenous (IV) iron hydroxide sucrose complex all patients were divided into 4 groups. In all patients before and after treatment we determined Hb, Ht, plasma levels of ferritin, erythropoietin (EPO), NT-proBNP, IL-1, IL-6, TNF-a, transferrin saturation (TS), total vascular peripheral resistance, and parameters of systolic and diastolic function of left ventricular (LV) myocardium (by echocardiography and doppler echocardiography). Results. In patients with NYHA class I-IV CHF and anemia increases of Hb, Ht, TS, levels of EPO and ferritin occurred during treatment by basic drugs combained with MEB. In subgroups of patients with NYHA class I-II and III-IV the 6-minute walk distance significantly increased by 25.1 and 38.3%, and GFR- by 24.5 and 14.9%, respectively. At the background of therapy with IV iron we observed significant increases of Hb, plasma level of ferritin, and TS. Combined treatment with MEB and IV iron was associated with positive dynamics of Hb, Ht, levels of ferritin, EPO, NT-proBNP, and IL-6. In this group in subgroups of patients with NYHA class I-II and III-IV the 6-minute walk distance significantly increased by 21.6 (p<0.001) and 64.9% (p<0.001), respectively. Conclusion. In the treatment of patients with CHF with anemia there is a need for differentiaion depending on such parameters as plasma levels of ferritin, EPO, and TS. In patients with CHF and anemia combined therapy with MEB and IV iron promotes significant positive dynamics of Hb, ferritin, TS and EPO, as well as of LV myocardial function parameters.